Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328983 | 0.92 | BACE1 (0.56) | BACE1BACE2KCNH2 | |
| SCHEMBL10329331 | 0.91 | BACE1 (0.56) | BACE1BACE2KCNH2 | |
| SCHEMBL10329263 | 0.91 | BACE1 (0.66) | BACE1BACE2KCNH2 | |
| SCHEMBL10328958 | 0.90 | BACE1 (0.59) | BACE1BACE2KCNH2 | |
| SCHEMBL10328960 | 0.90 | BACE1 (0.51) | BACE1BACE2 | |
| SCHEMBL10328947 | 0.88 | BACE1 (0.50) | BACE1BACE2 | |
| SCHEMBL10328959 | 0.88 | BACE1 (0.59) | BACE1BACE2 | |
| SCHEMBL10328967 | 0.88 | BACE1 (0.53) | BACE1BACE2 | |
| SCHEMBL10328914 | 0.88 | BACE1 (0.53) | BACE1BACE2KCNH2 | |
| SCHEMBL15892977 | 0.88 | BACE1 (0.49) | BACE1BACE2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475785-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150307465-A1 | Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use | MERCK SHARP & DOHME CORP. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307465-A1 | Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885NPC1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.